NCT06626256View on ClinicalTrials.gov

STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 5, 2025

Primary Completion Date

October 30, 2027

Study Completion Date

October 30, 2027

Conditions
Locally Advanced Cervical CarcinomaLocally Advanced Colorectal CarcinomaLocally Advanced Malignant Solid NeoplasmLocally Advanced MelanomaLocally Advanced Pancreatic Ductal AdenocarcinomaLocally Advanced Renal Cell CarcinomaMetastatic Cervical CarcinomaMetastatic Colorectal CarcinomaMetastatic Malignant Solid NeoplasmMetastatic MelanomaMetastatic Pancreatic Ductal AdenocarcinomaMetastatic Renal Cell CarcinomaStage II Pancreatic Cancer AJCC v8Stage III Cervical Cancer AJCC v8Stage III Colorectal Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8Stage III Renal Cell Cancer AJCC v8Stage IV Cervical Cancer AJCC v8Stage IV Colorectal Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8Stage IV Renal Cell Cancer AJCC v8Unresectable Cervical CarcinomaUnresectable Colorectal CarcinomaUnresectable Malignant Solid NeoplasmUnresectable MelanomaUnresectable Pancreatic Ductal AdenocarcinomaUnresectable Renal Cell Carcinoma
Interventions
BIOLOGICAL

Aldesleukin

Given SC

PROCEDURE

Biopsy

Undergo biopsy

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Computed Tomography

Undergo CT

DRUG

Cyclophosphamide

Given IV

PROCEDURE

Excisional Biopsy

Undergo excisional biopsy

DRUG

Fludarabine

Given IV

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

PROCEDURE

Standard Treatment

Receive standard of care therapy

BIOLOGICAL

Therapeutic Tumor Infiltrating Lymphocytes

Given STIL101 for injection IV

Trial Locations (1)

91010

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER